Trigeminal neuralgia

Dr. Zachary Johnson Joins Dallas Neurosurgical & Spine

Retrieved on: 
Wednesday, August 16, 2023
Phi Kappa Phi, Brain, Surgeon, Histology, University, North American Spine Society, Pathology, Trigeminal neuralgia, Spine, Medicine, Neurosurgery, Golf, Alpha Omega Alpha, National Military Family Association, Glioblastoma, Chiari malformation, Congress, Suite, The Society of Neurological Surgeons, University of Texas Southwestern Medical Center, American Association of Neurological Surgeons, MD, Patient, Congress of Neurological Surgeons, Radiosurgery, Fellow, Gold Humanism Honor Society, Sport, Biology, Hemifacial spasm, Mississippi College, United States Department of the Air Force, Malignancy, Football, Family, Neurology, University of Mississippi Medical Center, Nursing, Dentistry, Chiari

PLANO, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Zachary D. Johnson, MD, a fellowship-trained neurosurgeon, has joined Dallas Neurosurgical & Spine.

Key Points: 
  • PLANO, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Zachary D. Johnson, MD, a fellowship-trained neurosurgeon, has joined Dallas Neurosurgical & Spine.
  • “At Dallas Neurosurgical & Spine, our goal is to perform the least invasive, most effective procedure available, specifically tailored for each individual patient and their unique needs, and Dr. Johnson shares that care philosophy,” said Jeremy Denning, MD, a neurosurgeon with Dallas Neurosurgical & Spine.
  • Following medical school, Dr. Johnson completed both his residency in neurosurgery and a spine surgery fellowship at UT Southwestern Medical Center in Dallas.
  • Dallas Neurosurgical & Spine is the longest-running, privately held neurosurgical group in North Texas, with more than 50 years of experience caring for patients.

Lucy Scientific Discovery, Inc. Achieves Major Milestone with Successful Completion of its Acquisition of the Assets of Wesana Health

Retrieved on: 
Wednesday, July 5, 2023
Psilocybin, Trigeminal neuralgia, Partnership, Central nervous system, Depression, Therapy, Headache, Hope, Research, Brain, TG, CNS, Sale, Acquisition, MDD, Migraine, Patient, CBD, Lucy, Mental health, Pharmaceutical industry

VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. ("Lucy" or "the Company") (NASDAQ: LSDI) proudly announces the successful completion of its acquisition of Wesana Health Inc.'s ("Wesana") SANA-013 assets, marking a significant milestone in the field of mental health therapeutics.

Key Points: 
  • VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. ("Lucy" or "the Company") (NASDAQ: LSDI) proudly announces the successful completion of its acquisition of Wesana Health Inc.'s ("Wesana") SANA-013 assets, marking a significant milestone in the field of mental health therapeutics.
  • This acquisition strengthens Lucy's position as a leader in innovative drug development research and accelerates the development and commercialization of this groundbreaking treatment.
  • SANA-013 is being developed for the treatment of several mental health and central nervous system (CNS) related conditions, including Major Depressive Disorder (MDD), Migraine, Episodic Cluster Headaches, and Trigeminal Neuralgia (TG).
  • “I am pleased to announce the sale of our highly anticipated drug development program, SANA-013, to Lucy Scientific Discovery,” said Daniel Carcillo, Wesana founder and Chief Executive Officer.

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

Retrieved on: 
Wednesday, June 21, 2023
Columbia University, Seizure, Yale University, Tourette syndrome, Stuttering, University, Therapy, Central nervous system, Tic, Culture, Sofinnova, Physician, Trigeminal neuralgia, INVU (album), USD, CNS, TS, Axovant Sciences, Science, Pain, TSC, Columbia University Vagelos College of Physicians and Surgeons, Polaris Partners, Patient, Arvell Jones, Brown University, Surgeon, Faculty, Knowledge, Growth, Columbia University College of Dental Medicine, COFD, Psychiatry, Pfizer, Pharmaceutical industry, European, Noema

BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.

Key Points: 
  • BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.
  • “We are very excited that Ilise will be stepping into the CEO role at Noema Pharma.
  • Ilise has the expertise and experience to lead Noema as the Company enters its next phase of growth,” said Jeffrey Jonas, M.D., Chairman of Noema Pharma’s Board of Directors.
  • “I am thrilled to assume this leadership position with Noema Pharma at such a critical phase in the Company’s growth,” said Dr. Lombardo.

ZAP Surgical Announces Upcoming Installation of Novel Non-Invasive Brain Tumor Treatment System in South Korea

Retrieved on: 
Tuesday, June 13, 2023
Neurology, Radiology, Surgery, Oncology, Health, Medical Devices, Hospitals, Health Technology, SRS, Brain, Bed, Trigeminal neuralgia, Multimedia, Radiosurgery, Chiari malformation, Ministry, Stereotactic surgery, AVM, Patient, ZAP, Ministry of Health and Welfare (South Korea), Neurosurgery, Isotope, Medical imaging

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Dankook University Hospital (DKUH) in Cheonan, South Korea, is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Dankook University Hospital (DKUH) in Cheonan, South Korea, is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform.
  • The new oncology diagnosis and treatment facility is the only cancer center in the region.
  • With the addition of ZAP-X, DKUH will provide the latest advance in brain tumor care to patients throughout the country.
  • “As the sole cancer center in the Chungnam region, we play an important role in the treatment of brain tumors.

Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia

Retrieved on: 
Wednesday, May 31, 2023
Business development, Farooq, PALO, Research, KSA, Trigeminal neuralgia, PHN, CH, Risk, Neuropathic pain, Pain management, OTC, Islam, Therapy, Chronic pain, Pharmaceutical industry, Kingdom

Designated Territories will include Kingdom of Saudi Arabia.

Key Points: 
  • Designated Territories will include Kingdom of Saudi Arabia.
  • ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN).
  • ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.
  • “This agreement represents another critical milestone towards bringing our innovative non-opioid pain management medicines to people around the world,” said Jaisim Shah, President and Chief Executive Officer of Scilex.

Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region

Retrieved on: 
Monday, April 17, 2023
Logistics Cluster, AD Ports Group, PALO, ABU, ADPL, Trigeminal neuralgia, PHN, CH, Neuropathic pain, OTC, ADX, Therapy, AD, Chronic pain

CH Trading Group LLC will continue the process to expand commercialization of ZTlido® in the Middle East and North Africa markets and has the opportunity to distribute across the broader region and further expand the relationship for other products in Scilex’s non-opioid pain portfolio.

Key Points: 
  • CH Trading Group LLC will continue the process to expand commercialization of ZTlido® in the Middle East and North Africa markets and has the opportunity to distribute across the broader region and further expand the relationship for other products in Scilex’s non-opioid pain portfolio.
  • The master distributor agreement covers the distribution of ZTlido® in the United Arab Emirates, Qatar, Bahrain, Kuwait, Oman, and Egypt.
  • ZTlido® is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia (PHN).
  • ZTlido® was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.

EQS-News: Grünenthal GmbH: Grünenthal reports record revenue and profit in 2022 full-year results and strong pipeline progress

Retrieved on: 
Tuesday, March 28, 2023
Osteoarthritis, Diabetic neuropathy, Prednisolone, Partnership, Shionogi, PSNP, Social Security Government Pension Offset, Pain, Trigeminal neuralgia, Kyowa Kirin, EBITDA, Acquisition, NOP, Patient, Neuropathic pain, Corporation, Diversity, ESG, GRM, R, Social, Chronic pain, III, Selective glucocorticoid receptor modulator, Engagement, RTX, Inflammation, Pharmaceutical industry, Dentistry, Bayer, Environment

Aachen, Germany, 27 March 2023 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2022 full-year results, announcing record revenue and adjusted EBITDA.

Key Points: 
  • Aachen, Germany, 27 March 2023 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2022 full-year results, announcing record revenue and adjusted EBITDA.
  • In July 2022, an ESG rating agency placed Grünenthal in the top 3 percent of the pharmaceutical sub-industry, acknowledging the strong management of its ESG risks.
  • Following excellent employee engagement scores during the 2022 survey, Grünenthal has 24 entities worldwide certified as a Great Place to Work®.
  • In 2022, Grünenthal also made further progress in attracting and developing talents by launching a dedicated Diversity & Engagement strategy.

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

Retrieved on: 
Tuesday, March 21, 2023
Gout, Migraine, Partnership, Conversion, PALO, Celecoxib, YA, Securities and Exchange Commission (Philippines), Sale, First, Colchicine, Trigeminal neuralgia, VWAP, Patient, Korea Disease Control and Prevention Agency, Neuropathic pain, OTC, Nonsteroidal anti-inflammatory drug, Pain, FDA, Therapy, Chronic pain, Poultry farming, Security (finance), Pharmaceutical industry

The financing will enable further investment in Scilex’s non-opioid pain management portfolio, accelerating its mission to launch innovative non-opioid pain management products in major markets.

Key Points: 
  • The financing will enable further investment in Scilex’s non-opioid pain management portfolio, accelerating its mission to launch innovative non-opioid pain management products in major markets.
  • Scilex intends to use the proceeds to enhance the commercialization of Scilex’s three non-opioid pain management products for the treatment of acute and chronic pain.
  • Scilex’s suite of FDA-approved non-opioid pain management products include:
    ZTlido®, a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia.
  • Scilex has granted Yorkville registration rights requiring Scilex to register the resale of the shares of the underlying common stock.

Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health

Retrieved on: 
Tuesday, March 21, 2023
Psilocybin, Intellectual property, Trigeminal neuralgia, Drug development, Depression, Prevalence, Headache, Clinical trial, Brain, CNS, Acquisition, MDD, Migraine, Patient, Growth, Cannabidiol, Pharmaceutical industry, CBD

Lucy has agreed to acquire intellectual property and related assets for Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013, and Wesana’s supply of psilocybin which is sufficient to complete all near-term clinical studies.

Key Points: 
  • Lucy has agreed to acquire intellectual property and related assets for Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013, and Wesana’s supply of psilocybin which is sufficient to complete all near-term clinical studies.
  • As a result of this acquisition, Lucy will add drug development capabilities to its existing business of psychedelics manufacturing.
  • “We are excited to expand our footprint with the addition of Wesana’s SANA-013 drug development program,” said Lucy Scientific Discovery’s CEO Chris McElvany.
  • The prevalence of mental health disorders and other CNS-related conditions is growing significantly, resulting in increasing investment interest.

Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital

Retrieved on: 
Tuesday, March 7, 2023
Depression, Noema, Tourette syndrome, Stuttering, Investment, Polaris Partners, INVU (song), PDE10A, Glutamate (neurotransmitter), CHF, Myenteric plexus, Trigeminal neuralgia, Tuberous sclerosis complex tumor suppressors, CNS, Knowledge, Pain, Research, Seizure, Drug development, TSC, Patient, Sofinnova, News, Series, Central nervous system disease, General partnership, Atypical depression, COFD, Pharmaceutical industry

The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.

Key Points: 
  • The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.
  • Following the close of the Series B financing, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma.
  • USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
  • Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.